← FDA DRUG APPROVALS

FDA ANDA · ANDA203574

MESALAMINE

Sponsor: MYLAN

APPLICATION
ANDA203574
TYPE
ANDA
ORIGINAL APPROVAL
2018-11-20
LATEST ACTION
2020-05-20
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

MESALAMINEDiscontinued
MESALAMINE 1.2GM · TABLET, DELAYED RELEASE · ORAL

Approval history

2020-05-20Labeling · Supplement 1 · standardAP
2018-11-20UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →